News from the FDA/CDC

Adult diabetes up 35% over 25 years


 

The overall prevalence of diabetes increased 35% from 1988-1994 to 2011-2014 among adults aged 20 years and over, according the National Center for Health Statistics.

During 2011-2014, the age-adjusted prevalence of diabetes was 11.9% in adults aged 20 years and over, compared with 8.8% in 1988-1994. That 35% increase came despite a decrease in undiagnosed diabetes from 3.6% to 2.9% over that time period, which was not enough to offset a jump in physician-diagnosed disease from 5.2% to 9%, the NCHS reported in “Health, United States, 2016.”

Diabetes prevalence among adults aged 20 years and over
Although diabetes prevalence was up for each of the largest racial/ethnic groups, only the increase from 7.7% to 9.6% in non-Hispanic whites was statistically significant. Prevalence in non-Hispanic blacks rose from 16.3% to 18% from 1988-1994 to 2011-2014, and adults of Mexican origin saw an increase from 15.6% to 18%. Neither change was statistically significant, the NCHS said.

Undiagnosed diabetes dropped from 2.9% to 2% in whites and from 7.2% to 4.6% in blacks, but adults of Mexican origin saw a slight increase from 5% in 1988-1994 to 5.1% in 2011-2014. The physician-diagnosed side of the equation rose from 4.8% to 7.6% in whites, 9.1% to 13.4% in blacks, and 10.7% to 13% in those of Mexican origin, according to data from the National Health and Nutrition Examination Survey, which combines interviews and physical examinations, including laboratory analysis of blood samples.

Recommended Reading

DEVOTE: Degludec and glargine had similar risk with less severe hypoglycemia
MDedge Cardiology
CANVAS: Canagliflozin cuts cardiovascular events, doubles risk of amputations
MDedge Cardiology
Consistent weight benefits seen in empagliflozin use
MDedge Cardiology
ODYSSEY: Alirocumab improves lipids but not glycemic targets in 2DM
MDedge Cardiology
DURATION-8: Exenatide/dapagliflozin efficacy holds up at 1 year
MDedge Cardiology
SPRINT: Intensive BP control cut cardiovascular risk in patients with prediabetes
MDedge Cardiology
FDA advisory committee supports new CV liraglutide indication
MDedge Cardiology
LEADER post hoc analysis: Mechanism behind liraglutide’s cardioprotective effects unclear
MDedge Cardiology
Red flags for type 2 diabetes seen 25 years before diagnosis
MDedge Cardiology
Insulin degludec decreases rate, severity of hypoglycemic episodes
MDedge Cardiology

Related Articles